A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine
暂无分享,去创建一个
P. Delvenne | E. Hendrick | V. Bours | L. de Leval | C. Crum | O. Peulen | B. Koopmansch | F. Lambert | P. Hubert | P. Roncarati | M. Herfs | K. Segers | C. Quick | L. Vuitton | S. Valmary-Degano | C. Mougin | J. Prétet | F. Monnien | D. Guenat | D. Bruyère | A. Lebeau | Aurélie Poncin | William Penny | Nathalie Piazzon
[1] M. Plummer,et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.
[2] Yan Wang,et al. PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.
[3] P. Delvenne,et al. Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis , 2017, Viruses.
[4] Keith Lai,et al. Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma , 2017, The Journal of pathology.
[5] B. Falk,et al. A Semipersistent Plant Virus Differentially Manipulates Feeding Behaviors of Different Sexes and Biotypes of Its Whitefly Vector , 2017, Viruses.
[6] V. Dutta,et al. Mucinous adenocarcinoma of perianal region: an uncommon disease treated with neo-adjuvant chemo-radiation. , 2016, Translational gastroenterology and hepatology.
[7] Y. Akagi,et al. mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma , 2016, Case Reports in Oncology.
[8] D. Chan,et al. Case report of an anal adenocarcinoma arising from a perineal lump , 2016, Annals of medicine and surgery.
[9] D. van Baarle,et al. Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma , 2016, Future science OA.
[10] P. Delvenne,et al. Carcinogenic HPV infection in the cervical squamo‐columnar junction , 2015, The Journal of pathology.
[11] J. Beijnen,et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53 , 2015, British Journal of Cancer.
[12] F. McKeon,et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk , 2015, Modern Pathology.
[13] J. Foidart,et al. Altered α‐defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour‐permissive microenvironment , 2014, The Journal of pathology.
[14] E. Pirog,et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases , 2014, Modern Pathology.
[15] E. Høgdall,et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Coppedè,et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens , 2014, Epigenetics.
[17] T. Sakamoto,et al. Adenocarcinoma arising from an anal gland-Report of a case. , 2014, International journal of surgery case reports.
[18] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[19] R. Sun,et al. P16INK4A as a surrogate biomarker for human papillomavirus‐associated oropharyngeal carcinoma: Consideration of some aspects , 2013, Cancer science.
[20] D. Sebag‐Montefiore,et al. Adenocarcinoma of the anal canal – a systematic review , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[21] Nikhil Wagle,et al. Oncogenic mutations in cervical cancer , 2013, Cancer.
[22] M. Ducreux,et al. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. , 2013, Cancer treatment reviews.
[23] F. McKeon,et al. Cervical Squamocolumnar Junction–specific Markers Define Distinct, Clinically Relevant Subsets of Low-grade Squamous Intraepithelial Lesions , 2013, The American journal of surgical pathology.
[24] J. Bosset,et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. , 2013, Human pathology.
[25] M. Márquez,et al. Adenocarcinoma del canal anal. Revisión de conjunto , 2013 .
[26] J. Ledermann,et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.
[27] M. Márquez,et al. Adenocarcinoma of the anal canal. Narrative review , 2013 .
[28] N. Merrett,et al. Transcriptionally Active Human Papillomavirus Is Strongly Associated With Barrett's Dysplasia and Esophageal Adenocarcinoma , 2013, The American Journal of Gastroenterology.
[29] Levi Waldron,et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum , 2012, Gut.
[30] M. Poljak,et al. Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. , 2011, Journal of virological methods.
[31] E. Dozois,et al. Neoplasms of Anal Canal and Perianal Skin , 2011, Clinics in colon and rectal surgery.
[32] V. Karantza,et al. Keratins in health and cancer: more than mere epithelial cell markers , 2011, Oncogene.
[33] R. Gonzalez,et al. A Twenty-Year Experience with Adenocarcinoma of the Anal Canal , 2009, Diseases of the colon and rectum.
[34] P. Delvenne,et al. Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? , 2009, Trends in molecular medicine.
[35] H. Nemoto,et al. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. , 2009, Anticancer research.
[36] J. B. Carpenter,et al. Immunophenotypic characteristics of anal gland carcinoma. , 2009, Archives of pathology & laboratory medicine.
[37] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[38] P. Delvenne,et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. , 2008, The American journal of pathology.
[39] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[40] K. Cymes,et al. Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. , 2007, Archives of pathology & laboratory medicine.
[41] J. Berlin,et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. , 2007, Clinical colorectal cancer.
[42] L. Akslen,et al. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients , 2006, International journal of cancer.
[43] E. Friedman,et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Hoheisel,et al. Array-based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines , 2005, Nucleic acids research.
[45] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[46] A. Duval,et al. Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.
[47] Sudhir Srivastava,et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.
[48] R. Mirimanoff,et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. , 2003, International journal of radiation oncology, biology, physics.
[49] E. Lin,et al. Chemoradiation for adenocarcinoma of the anus. , 2003, International journal of radiation oncology, biology, physics.
[50] A. Hongo,et al. Rapid and Sensitive Detection of Physical Status of Human Papillomavirus Type 16 DNA by Quantitative Real-Time PCR , 2002, Journal of Clinical Microbiology.
[51] N. Petrelli,et al. Prognosis and recurrence patterns of anal adenocarcinoma. , 1995, American journal of surgery.
[52] M. Abel,et al. Adenocarcinoma of the anal glands , 1993, Diseases of the colon and rectum.
[53] V. Knysh,et al. [Adenocarcinoma of the anal canal]. , 1986, Voprosy onkologii.
[54] L. Gissmann,et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. , 1983, Proceedings of the National Academy of Sciences of the United States of America.